Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Neovascularization

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    171 result(s) found for: Neovascularization. Displaying page 6 of 9.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2006-002977-33 Sponsor Protocol Number: Luc01AKSI Start Date*: 2006-06-22
    Sponsor Name:University Eye Hospital
    Full Title: Safety and efficacy of intravitreal injections of ranibizumab/Lucentis in combination with verteporfin photodynamic therapy (PDT) in patients with choroidal neovascularisation (CNV) secondary to ag...
    Medical condition: Age related macular degeneration (AMD) is the leading cause of blindness in individuals older than 50 years in the developed world. Eighty to ninety percent of rapid and severe vision loss due to A...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005439-10 Sponsor Protocol Number: RabOCT Start Date*: 2013-08-30
    Sponsor Name:University of Leipzig Ritterstr. 26, 04109 Leipzig
    Full Title: Re-treatment with intravitreal application of ranibizumab guided by morphological macular changes documented by optical coherence tomography (OCT) in patients with macular edema due to branch retin...
    Medical condition: macular edema secondary to branch retinal vein occlusion (BRVO)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004853 10054467 Macular edema LLT
    18.1 100000004853 10038906 Retinal vein branch occlusion LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001971-36 Sponsor Protocol Number: RETAANE PED Start Date*: 2005-05-25
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: PILOT, OPEN NON COMPARATIVE CLINICAL STUDY TO EVALUATE THE EFFICAY AND SAFETY OF RETAANE (ANECORTAVE ACETATO 15 MG, 0.5 ML DI 30 MG/ML ANECORTAVE ACETATO STERILE SUSPENSION) IN PATIENTS WITH COROID...
    Medical condition: RETAANE TREATMENT OF COROIDEAL NEOVASCULARIZATION FORMS SECONDARY TO SENILE MACULAR DEGENERATION
    Disease: Version SOC Term Classification Code Term Level
    6.1 10015919 SOC
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-001344-11 Sponsor Protocol Number: CCD-GPLSCD01-03-FU Start Date*: 2018-04-11
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: Multinational, multicenter, prospective, long-term safety and efficacy follow-up study after Autologous Cultivated Limbal Stem Cells Transplantation (ACLSCT) for restoration of corneal epithelium i...
    Medical condition: corneal lesions with associated moderate to severe limbal stem cell deficiency due to ocular burns
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10011012 Corneal epithelium opacity LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PL (Completed) FR (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) NL (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000598-30 Sponsor Protocol Number: CS001-EU01 Start Date*: 2012-03-06
    Sponsor Name:Cellseed France S.A.R.L.
    Full Title: MULTICENTER STUDY OF CULTURED AUTOLOGOUS ORAL MUCOSAL EPITHELIAL CELL-SHEET (CAOMECS) TRANSPLANTATION TO PATIENTS WITH TOTAL LIMBAL STEM CELL DEFICIENCY
    Medical condition: Limbal Stem Cell Deficiency of the Eye
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10063581 Stem cell transplant PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Ongoing) AT (Prematurely Ended) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-010973-19 Sponsor Protocol Number: 14130 Start Date*: 2009-09-24
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized, double-masked, sham-controlled phase 3 study of the efficacy, safety, and tolerability of repeated intravitreal administration of VEGF Trap-Eye in subjects with macular edema secondar...
    Medical condition: Maculare edema secondary to Central Retinal Vein Occlusion
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10054467 Macular edema LLT
    14.1 10015919 - Eye disorders 10007972 Central retinal vein occlusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) HU (Completed) LV (Completed) DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003763-22 Sponsor Protocol Number: BAY73-4506/15984 Start Date*: 2014-07-02
    Sponsor Name:Bayer HealthCare AG
    Full Title: A combined Phase IIa / IIb study of the efficacy, safety, and tolerability of repeated topical doses of regorafenib eye drops, in treatment-naïve subjects with neovascular age related macular degen...
    Medical condition: neovascular age related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    18.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    18.0 10015919 - Eye disorders 10064930 Age-related macular degeneration PT
    18.0 10015919 - Eye disorders 10025409 Macular degeneration PT
    18.0 10015919 - Eye disorders 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004567-30 Sponsor Protocol Number: 1313.20 Start Date*: 2014-04-15
    Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG
    Full Title: A single arm open label study to evaluate the pharmacodynamics and safety of a 4 wk treatment with BI 144807 in patients with newly diagnosed wet age related macular degeneration (wAMD)
    Medical condition: patients with newly diagnosed, unilateral, wet Are-Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004853 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-003517-33 Sponsor Protocol Number: CRFB002A2302 Start Date*: 2005-11-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-masked, active-controlled, multicenter study comparing the efficacy and safety of ranibizumab (0.3 mg and 0.5 mg) administered as two dosing regimens in patients with subfoveal...
    Medical condition: Male and female patients ≥50 years of age with either with predominantly classic, minimally classic, or occult lesions with no classic component, all with primary or recurrent subfoveal CNV seconda...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) DE (Completed) ES (Completed) PT (Completed) GB (Completed) CZ (Completed) IT (Completed) BE (Completed) FI (Completed) SE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2009-013062-11 Sponsor Protocol Number: AR-OCUL-1 Start Date*: 2007-03-29
    Sponsor Name:AZIENDA USL 8 AREZZO
    Full Title: BEVACIZUMAB COMBINED WITH PDT, VERSUS RANIBIZUMAB AND PEGAPTANIB BOTH COMBINED WITH PDT FOR NEOVACULAR AGE RELATED MACULAR DEGENERATION CLINICAL TRIAL
    Medical condition: Neovascular Age Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015902 Exudative senile macular degeneration of retina LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-006182-14 Sponsor Protocol Number: Start Date*: 2006-02-20
    Sponsor Name:UNIVERSITA DEGLI STUDI DI UDINE
    Full Title: Intravitreal Bevacizumab Avastin, Roche, United Kingdom for exudative maculopathies
    Medical condition: Exudative maculopathy associated with retinovascular disease
    Disease: Version SOC Term Classification Code Term Level
    6.1 10012689 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-006290-90 Sponsor Protocol Number: AU-06102G Start Date*: 2008-10-10
    Sponsor Name:Society (Institute) for clinical research
    Full Title: Subretinal Macugen for neovascular age-related macular degeneration (SUMANA)
    Medical condition: Neovascular (exudative) age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015902 Exudative senile macular degeneration of retina LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-015681-55 Sponsor Protocol Number: C-09-023 Start Date*: 2010-03-18
    Sponsor Name:Alcon Research, Ltd.
    Full Title: A Dose-Escalation Study of AL-39324 Suspension versus Lucentis™ for the Treatment of Exudative Age-Related Macular Degeneration
    Medical condition: Exudative Age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10067791 Wet macular degeneration LLT
    14.0 10015919 - Eye disorders 10025409 Macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004959-39 Sponsor Protocol Number: CRFB002A2405 Start Date*: 2013-05-10
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 24-month, phase IIIb, randomized, double-masked, multicenter study assessing the efficacy and safety of two treatment regimens of 0.5 mg ranibizumab intravitreal injections guided by functional a...
    Medical condition: Visual impairment due to neovascular AMD
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) LT (Prematurely Ended) ES (Prematurely Ended) IE (Prematurely Ended) DE (Prematurely Ended) SK (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) GB (Prematurely Ended) GR (Completed) SE (Completed) FI (Completed) PT (Completed) HU (Completed) NL (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-001281-33 Sponsor Protocol Number: RGHT000449 Start Date*: 2007-07-09
    Sponsor Name:Belfast Health and Social Care Trust [...]
    1. Belfast Health and Social Care Trust
    2. Queen's University Belfast, Research and Regional Services
    Full Title: A randomised control trial of alternative treatments to Inhibit VEGf in Age-related choroidal Neovascularisation(IVAN)
    Medical condition: Choroidal neovascularisation in age related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10015902 Exudative senile macular degeneration of retina LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-021968-15 Sponsor Protocol Number: ID_2909 Start Date*: 2010-08-06
    Sponsor Name:AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
    Full Title: NOT RANDOMISED OPEN LABEL STUDY TO COMPARE EFFICACY OF BEVACIZUMAB (AVASTIN, ROCHE) VERSUS RANIBIZUMAB (LUCENTIS, NOVARTIS) ADMINISTERED BY INTRAVITREAL INJECTION IN PATIENTS WITH EXUDATIVE AGE REL...
    Medical condition: exudative age related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015902 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019183-36 Sponsor Protocol Number: CFD4870g Start Date*: 2011-06-16
    Sponsor Name:GENENTECH, Inc.
    Full Title: A PHASE Ib/II, MULTICENTER, RANDOMIZED, SINGLE-MASKED, SHAM INJECTION−CONTROLLED STUDY OF SAFETY, TOLERABILITY, AND EVIDENCE OF ACTIVITY OF FCFD4514S INTRAVITREAL INJECTIONS ADMINISTERED MONTHLY OR...
    Medical condition: Geographic Atrophy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10063947 Geographic atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001544-31 Sponsor Protocol Number: PATP1001 Start Date*: 2007-04-12
    Sponsor Name:Moorfields Eye Hospital
    Full Title: A randomised, double-masked, phase 3 study of the efficacy and safety of Avastin® (bevacizumab) intravitreal injections compared to best available therapy in subjects with choroidal neovasculariza...
    Medical condition: Exudative age-related macular degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-012509-20 Sponsor Protocol Number: MERLOT Start Date*: 2009-07-28
    Sponsor Name:King's College Hospital NHS Foundation Trust
    Full Title: A randomised controlled trial of epimacular brachytherapy versus ranibizumab monotherapy for the treatment of subfoveal choroidal neovascularisation associated with wet age-related macular degenera...
    Medical condition: Wet age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    12.0 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-000536-28 Sponsor Protocol Number: C-10-083 Start Date*: 2011-09-12
    Sponsor Name:Alcon Research Ltd.
    Full Title: Safety and efficacy study with ESBA1008 versus Lucentis for the treatment of exudative age-related macular degeneration
    Medical condition: wet age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10064930 Age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 09 19:24:19 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA